一个与甲基化相关的基于IncRNA的预测模型,用于肺腺癌
Kun Yang1,2, Hao Liu3, Jun Hai Li2,3
1Thoracic Surgery, The Thirteenth People's Hospital of Chongqing City, Chongqing City, China.
The clinical respiratory journal
|August 27, 2024
概括
这项研究开发了一种新的甲基化相关的长非编码RNA (lncRNA) 签名,用于肺腺癌 (LUAD). 这个签名准确地预测了患者的预后,并指导了个性化的治疗策略.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 异常的DNA甲基化与肺腺癌 (LUAD) 的发展密切相关.
- 长非编码RNA (lncRNAs) 在生物功能中起着至关重要的作用,并作为潜在的癌症生物标志物.
- 需要基于与甲基化相关的 lncRNAs 来为 LUAD 提供强大的预后特征.
研究的目的:
- 构建可靠的甲基化相关的lncRNA特征,用于预测LUAD患者的预后.
- 调查与签名相关的潜在分子机制和免疫透.
- 探索签名在为LUAD指导个性化化疗中的潜力.
主要方法:
- 利用TCGA LUAD数据上的Cox回归和Kaplan-Meier分析来开发一个预后签名.
- 使用基因组丰富分析 (GSEA) 和单样GSEA (ssGSEA) 进行功能和免疫透分析.
- 使用专门的生物信息学工具分析了SNP位点,转录因子相互作用和miRNA结合.
主要成果:
- 确定了一种与18-甲基化相关的lncRNA特征,有效预测LUAD预后,并区分高风险患者.
- 与临床病理学参数相比,该签名显示出更高的预测能力.
- 丰富的途径包括EMT,缺氧,干性和增殖;观察到与免疫状况和个性化化疗的显著关联.
结论:
- 开发的甲基化相关的lncRNA特征是预测LUAD预后和复发的强有力的工具.
- 该签名提供了关于瘤生物学和免疫透的见解,有助于个性化治疗策略.
- 这一签名有望指导LUAD患者个性化化疗方案.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
03:18Non-LTR Retrotransposons
11.4K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.4K